A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
AstraZeneca
Hoffmann-La Roche
OncoC4, Inc.
Revolution Medicines, Inc.
USWM, LLC (dba US WorldMeds)
Seagen Inc.
Merck Sharp & Dohme LLC
Agenus Inc.
Eisai Inc.
GlaxoSmithKline
Atavistik Bio, Inc
AbbVie
AstraZeneca
GlaxoSmithKline
Gilead Sciences
AstraZeneca
Incyte Corporation
NeoTX Therapeutics Ltd.
SystImmune Inc.
Merck Sharp & Dohme LLC
Exelixis
GlaxoSmithKline
Merck Sharp & Dohme LLC
Eli Lilly and Company
Klus Pharma Inc.
Tempus AI
Theratechnologies
Xencor, Inc.
Checkpoint Therapeutics, Inc.
Carisma Therapeutics Inc
NextCure, Inc.
Merck Sharp & Dohme LLC
NETRIS Pharma
Cornerstone Robotics